#ESGCT2025
LightNews LightNews
dlwagner.bsky.social
@dlwagnerlabs.bsky.social on tour! 🌍🇩🇪🇺🇸

We had a great time at the Annual Congress of the European Society for Gene and Cell Therapy #ESGCT2025 in Sevilla. 🇪🇸

Super proud of everyone who presented their projects & grateful for working with this amazing team: science and good vibes! 🧬🧪💙
October 12, 2025 at 1:45 PM
ivankrivega.bsky.social
Official press release for @sonothera.bsky.social presentation @ #ESGCT2025.

Results show high levels of durable human dystrophin protein expression exceeding
50% of endogenous levels have been achieved in NHP.

Poster Session 2, Oct 9th. Poster P0266.

#Dmd #GeneTherapy #nonviral
sonothera.bsky.social SonoThera @sonothera.bsky.social · Oct 7
SonoThera™ Presents New Data at ESGCT 2025 Demonstrating Expression of Full-Length Human Dystrophin Using Targeted, Ultrasound-Mediated Delivery to Treat Duchenne Muscular Dystrophy - www.businesswire.com/news/home/20...
October 7, 2025 at 6:40 PM
ivankrivega.bsky.social
Efficient EGFP reporter transgene delivery to NHP T cells by LNP. Next step is delivering the CAR in vivo

#ESGCT2025 #InVivoCART

Cecilia Cotta-Ramusino
@TesseraTx
October 8, 2025 at 10:29 AM
scienceboss.bsky.social
#ESGCT2025: A woman who was previously ineligible for @genethonfr.bsky.social's Crigler–Najjar syndrome gene therapy due to pre-existing immunity to AAV8 got the treatment after Hansa Bio's antibody-chopping drug imlifidase cleared the way. Read more in @endpts.com :

endpoints.news/new-study-su...
Person previously ineligible for gene therapy granted treatment after antibody-chopping drug clears the way
Study shows Hansa's Idefirix helps deliver Genethon's AAV8 gene therapy GNT003 in previously ineligible Crigler-Najjar patient by clearing antibodies, reports Do Cao at ESGCT.
endpoints.news
October 10, 2025 at 7:16 PM
scienceboss.bsky.social
At #ESGCT2025, the scientists behind Baby KJ’s custom #CRISPR gene editing therapy said they are planning a clinical trial to help more children and turn the one-off drug into an approvable, repeatable procedure. My story for @endpts.com has more details. - endpoints.news/qa-scientist...
Q&A: The scientists behind Baby KJ’s custom CRISPR drug are planning a trial to help more children
Scientists led by Kiran Musunuru plan clinical trial for custom gene editing therapies, following success with
endpoints.news
October 9, 2025 at 10:17 AM
dggzt.bsky.social
We are proud to see young German researchers presenting their exciting work at ESGCT:

🎤 Presentations:
Akshatha Shivaraj
Kerstin Geiger

🖼️ Posters:
Stylianos Michalakis
Fabian John
Muhammed Burak Demircan
Maren Soldierer
Alexandre Trubert
Melissa Whitehead

#DGGTeV #GeneTherapy #ESGCT2025
October 6, 2025 at 2:00 PM
scienceboss.bsky.social
I am heading to Spain next week to cover the #ESGCT2025 meeting for @endpts.com. If you're presenting new cell therapy, gene therapy, gene editing or RNA therapy research at the meeting, or just want to meet, reach out!
October 2, 2025 at 12:45 PM
genethonfr.bsky.social
[ESGCT CONGRES]
🎉 Du 7 au 10 octobre, @genethonfr.bsky.social sera à l'honneur lors du congrès #ESGCT2025 à Séville !
🔬 4 présentations orales, 19 posters – 2 sessions co-présidées.
🌍 Rencontrons-nous!
👉Actualité : urlr.me/aWVrAE
#Genethon #DMD #MaladiesRares #Recherche
October 1, 2025 at 2:05 PM
genethonfr.bsky.social
[ESGCT CONGRESS]
🎉 From Oct 7–10, @genethonfr.bsky.social
takes center stage at #ESGCT2025 in Seville!
🔬 4 oral presentations, 19 contributions – 2 co-chaired sessions
🌍 Let’s connect, share & inspire!
👉Read the full news : urlr.me/G9t7mv
#Genethon #DMD #RareDiseases #Research
October 1, 2025 at 2:02 PM
scienceboss.bsky.social
At #ESGCT2025, Seppo Ylä-Herttuala from the University of Eastern Finland reported success in Phase 2b study of a gene therapy that uses a surgical technique to inject adenoviruses containing the VEGF-D gene into ischemic heart tissue. My story for @endpts.com:

endpoints.news/finnish-rese...
Finnish researchers report success in mid-stage study of heart disease gene therapy
Researchers from the University of Eastern Finland said a gene therapy for people with refractory angina, a form of chronic chest pain that persists despite treatment, was successful in a Phase 2b stu...
endpoints.news
October 9, 2025 at 12:49 PM
jyves94.bsky.social
⚡️ #Cellectis présentera des données sur son programme de thérapie génique non-virale et sur des TALE Base Editors lors du congrès annuel de l’European Society of Cell and Gene Therapy #ESGCT2025, qui se tiendra du 7 au 10 octobre 25 à #Séville, #Espagne
www.boursica.com/informations...
October 7, 2025 at 6:46 AM
christiangebhard.com
With #FindMe2care we connect patients with rare genetic diagnoses to research, clinical trials, and patient organizations.

Excited to present our platform at #ESGCT2025! Curious? Let's chat during breaks or meet me at the poster session tomorrow, P1111.

www.findme2care.de/en/english/
FindMe2care – Diagnosis-related medicine for rare genetic diseases
www.findme2care.de
October 7, 2025 at 9:21 PM
dggzt.bsky.social
Visit our booth in the Registration Hall & test your skills in our daily Pipetting Game 🧪
Beat our board member Prof. Anja Ehrhardt!

Our game ist open:
📅 Every day
⏰ 10:30 AM – 05:30 PM

Each day’s top pipetter will get a prize at the end of the day from our Microbes plushies🦠
#ESGCT2025 #DGGZTeV
October 7, 2025 at 1:04 PM
magic-horizon.bsky.social
🔬 Earlier this month at #ESGCT2025, MAGIC partners
@crick.ac.uk
shared 3 posters on human models for neuromuscular gene therapy:

🧪 3D cultures for DMD
🧠 AAV dynamics in multi-organoids
🧬 Myotubular myopathy modelling

Pushing boundaries in patient-relevant research.

#genetherapy #MagicProject
Images of 3 different presenters standing in front of their posters at ESGCT 2025
October 22, 2025 at 8:30 AM
scienceboss.bsky.social
At #ESGCT2025, Mammoth Bio presented the first monkey data of its lead program, a gene editing therapy that uses its small Cas-Phi enzyme to target APOC3 for triglyceride reduction. A clinical trial is planed for the second half 2026. More in my story for @endpts.com:

endpoints.news/mammoth-bios...
Mammoth Biosciences is getting closer to finding out if its big bet on tiny CRISPR enzymes will pay off
Mammoth Biosciences reveals monkey data for CRISPR therapy targeting APOC3 gene to lower triglycerides, with CEO Trevor Martin planning clinical trials in 2026.
endpoints.news
October 9, 2025 at 2:31 PM
clearpointneuro.bsky.social
It’s been another great #ESGCT meeting, and there’s still time to catch up with the #ClearPoint team at Booth C03 tomorrow. If you didn’t make it to the conference, we’re always available for an online meeting! #ESGCT2025 #CLPT
October 9, 2025 at 4:39 PM
clearpointneuro.bsky.social
Join our Biologics team this week at Booth C03 in Seville, Spain for #ESGCT to hear about our latest innovations and how #ClearPoint is leading the way for delivery of gene and cell therapies from discovery to commercialization! #ESGCT2025 #CLPT
October 6, 2025 at 4:35 PM
nucleaselab.bsky.social
This year, I am not joining colleagues at #CGMesa25 or #ESGCT2025, but here in Boston for 𝐅𝐢𝐞𝐫𝐜𝐞 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐖𝐞𝐞𝐤 #FBW2025.
Please let me know if you are also attending and want to meet up this week!
#CRISPR in #Boston
October 6, 2025 at 10:45 PM
scribetx.bsky.social
Missed our presentation on Scribe’s ELXR (epigenetic editor) technology at #ESGCT2025?

Catch up with this BioWorld article highlighting how we engineered our ELXR platform for enhanced potency and its therapeutic application in durably targeting PCSK9.

www.bioworld.com/articles/725...
Epigenetic approach shows durable PCSK9 silencing in primates
A preclinical study presented at the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), held in Seville Oct. 7-10, showed a new epigenetic editing technology that enables d...
www.bioworld.com
October 16, 2025 at 6:54 PM
scribetx.bsky.social
We’re headed to #ESGCT2025 to share our latest #CRISPR #EpigeneticEditing data. Check out our presentation on Thursday, Oct. 9!

🧬 Engineering enhanced epigenetic editors: novel repressor domains drive potent and durable therapeutic gene silencing in non-human primates
October 6, 2025 at 5:01 PM
institutdemyologie.bsky.social
#ESGCT2025 Experts from @institutdemyologie.bsky.social participated to the ESGCT 32nd Annual Meeting in Seville to present their work and results ➡️www.institut-myologie.org/en/2025/09/15/researchers-from-the-institute-attending-the-esgct-conference/

@crm-myologie.bsky.social
October 10, 2025 at 8:35 PM
magic-horizon.bsky.social
🔬 MAGIC at #ESGCT2025!

DINAMIQS shared how mass photometry boosts AAV packaging efficiency & stability.

📌 >95% full capsids = better stress resilience.
🚀 Fast, label-free AAV quality checks = smarter upstream optimisation.

#MAGICProject #GeneTherapy #AAV
Marco Wachowius from DINAMIQS stands in front of the poster titled "Single-Particle Analysis of AAV Vectors by Mass Photometry: Insights into Packaging Efficiency and Stability"
October 16, 2025 at 9:54 AM
magic-horizon.bsky.social
Are you attending #WMS2025 or #ESGCT2025 this week? 🔬

Make sure you check out the presentations from MAGIC members to learn more about the project and how we’re aiming to accelerate the development of gene therapies for rare neuromuscular conditions.

🧵⬇️
Check out MAGIC presentations! WMS 10:00 - 10:15 10 October Francesco Saverio Tedseco Towards a human multi-organoid platform to develop and assess specificity, toxicity and efficacy of neuromuscular gene therapies Posters at ESGCT P0287 - Mariam Zhouhair P0010 - Sumitava Dastidar P0373 - Leah Zerlin
October 8, 2025 at 11:58 AM
magic-horizon.bsky.social
Headed to #WMS2025 or #ESGCT2025 next week? 🧬✈️

Members from MAGIC will be attending both – keep an eye out for posters and presentations to learn more about the project.

We’re looking forward to connecting with researchers, clinicians, and collaborators across both events! 🤝
Image of Vienna and Seville with the test overlayed: MAGIC is attending WMS and ESGCT next week.
October 2, 2025 at 9:32 AM
drtimos.bsky.social
Thrilled by the momentum at #ESGCT2025, from AI-guided capsids to real durability signals across liver, ocular, and CNS. Science is maturing, access must follow. #LucidQuest's preview here: bit.ly/48zSu9d
#GeneTherapy #CellTherapy #AIinHealthcare
ESGCT 2025_Preview_by_LucidQuest.pdf
bit.ly
October 6, 2025 at 2:36 PM